• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » EMD Millipore to acquire Biochrom

EMD Millipore to acquire Biochrom

August 23, 2012
CenterWatch Staff

EMD Millipore, the life science division of Merck of Darmstadt, Germany, has decided to acquire Biochrom, a cell culture media specialist of Berlin, Germany. The closing price was not disclosed.

Biochrom employs 60 employees and had 2011 sales of approximately $16.3 million. The acquisition will strengthen EMD Millipore’s process solutions business unit, which provides products, services and solutions that simplify production complexity for pharmaceutical and biopharmaceutical manufacturers. Biochrom’s cell-culture media products are highly complementary, adding liquid cell-culture media and buffers including serum-free products and disposable packaging solutions to the existing portfolio.

 “With Biochrom we have a great opportunity to deliver an expanded portfolio of cell-culture media products to our global customers and address a growing demand for ready-to-use liquid solutions that drive safety and efficiency in the development and manufacture of clinical and commercial drug materials,” said Robert Yates, head of the EMD Millipore division.

Dr. Bernd Frenzel, CEO of Biochrom, added, “EMD Millipore is the ideal partner for Biochrom. With EMD Millipore we will be able to leverage their industry relationships and global footprint to reach more customers and offer a more comprehensive portfolio of media and buffers."

EMD Millipore will maintain Biochrom’s operations in Berlin. Closing of the transaction is expected in the fourth quarter of 2012.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing